Technologies such as positron emission topography combined with computational tomography (PET/CT) go beyond the simple imaging of tumour location and size to allow visualization of blood vessel formation, cell division, and even the presence of specific molecules such as hormone receptors.

My research programme encompasses several breast cancer clinical trials; the overall aim is to determine how combining PET/CT imaging with conventional genetic tumour classification can improve decision making and prognosis assessment for women with hormone-responsive breast tumours. I am also involved in testing novel markers that can be used in PET/CT imaging to further characterize breast tumours.